I2 | ERO1A inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $75.00 | ||
| 25 mg | $260.00 |
I2 is an inhibitor of the oxidoreductase ERO1A (IC50 = 8.1 µM), a mediator of the unfolded protein response (UPR).1 Under cancer-related hypoxia conditions, ERO1A favors the folding of the angiogenic protein VEGFA leading to cancer cell growth and spread. I2 inhibited the metabolic activity of DMA-MB-231 triple negative breast cancer cells and impaired migration and VEGF secretion. Tumors in C57/BL6Jmice showed decreased levels of VEGF and PD-L1 when treated with I2.
References/Citations:
- Varone et al. (2025), Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment; Cell Death Dis. 16 105
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
I2 is an inhibitor of the oxidoreductase ERO1A (IC50 = 8.1 µM), a mediator of the unfolded protein response (UPR).1 Under cancer-related hypoxia conditions, ERO1A favors the folding of the angiogenic protein VEGFA leading to cancer cell growth and spread. I2 inhibited the metabolic activity of DMA-MB-231 triple negative breast cancer cells and impaired migration and VEGF secretion. Tumors in C57/BL6Jmice showed decreased levels of VEGF and PD-L1 when treated with I2.
References/Citations:
- Varone et al. (2025), Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment; Cell Death Dis. 16 105
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass